Skip to main content
. Author manuscript; available in PMC: 2022 Jun 1.
Published in final edited form as: Cancer Res. 2021 Sep 30;81(23):6018–6028. doi: 10.1158/0008-5472.CAN-21-0030

Figure 6. DAC/ENT combination treatment targeted SALL4 negative cancer cells in vivo.

Figure 6.

(A) Schema of sequential drug treatment in a murine xenograft model. (B) Tumor growth measured at different time points. (C) Tumor volume measured at the end point from the indicated treatment groups. (D) Image of tumors harvested from mice with H1299 cells xenotransplantation after indicated treatment. (E) Tumor weights and (F) body weights from indicated groups. n.s. means P>0.05, *P<0.05, **P<0.01, ***P<0.001.